(Q53137288)

English

A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.

scientific article published on 17 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

1 reference

based on heuristic

inferred from title

2

object named as

Irit Avivi

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

author name string

Avichai Shimoni

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Jacob M Rowe

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Moshe Yeshurun

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Itai Levi

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Reuven Or

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Paulina Patachenko

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Abraham Avigdor

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Tzila Zwas

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Arnon Nagler

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

language of work or name

0 references

publication date

17 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

118

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

19

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

4706-4714

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

21 January 2018

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

7 January 2021

based on heuristic

inferred from DOI database lookup

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27418

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27418

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22252613

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53137288&oldid=1551090846"